echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > First-line cervical cancer: Hengrui PD-L1/TGFβ bifunctional fusion protein starts phase III clinical trials

    First-line cervical cancer: Hengrui PD-L1/TGFβ bifunctional fusion protein starts phase III clinical trials

    • Last Update: 2022-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 23, the Insight database showed that Hengrui Medicine launched a phase III clinical trial to explore the combination of PD-L1/TGFβ bifunctional fusion protein SHR-1701 combined with chemotherapy and bevacizumab-like drug BP102 as the first-line treatment for cervical cancer


    From: Insight database (http://db.


    In November, SHR-1701 has successively launched 3 late-stage clinical trials, including a phase II/III clinical phase for perioperative treatment of gastric cancer, a phase III clinical phase for non-squamous non-small cell lung cancer, and the first-line treatment just announced Phase III clinical of cervical cancer


    SHR-1701 domestic phase III and phase II/III clinical

    From Insight database (http://db.


    SHR-1701 is an anti-PD-L1/TGF-βRII bifunctional fusion protein independently developed by Hengrui Medicine.


    According to the Insight database, the drug is advancing rapidly, and it was first reported for clinical trials in 2018, and clinical trials started in the same year


    SHR-1701 project time axis

    From: Insight database (http://db.


    At the 2021 ESMO conference, Hengrui has announced the cervical cancer expansion cohort (cohort4) data of SHR-1701 for advanced solid tumor phase I (Abstract number: 776P, clinical trial registration number: NCT03774979)


    As of February 26, 2021, the median exposure time of SHR-1701 was 12 weeks (3.


    Hengrui's SHR-1701 is the second PD-L1/TGFβ dual-target drug in the world's research and development progress, and the first is Merck's M7824


    The results showed that the ORR assessed by RECIST v1.


    The published clinical data has preliminarily confirmed the therapeutic potential of PD-(L)1/TGFβ drugs in the field of cervical cancer.


    The popularity of the target combination of PD-L1/TGFβ is well known, and now at least 12 domestic enterprise projects have entered the clinical stage


    Progress of new domestic drugs for PD-(L)1/TGFβ

    From Insight database (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.